10 |
strains of bacteria. The program is currently keeping pace with its ambitious |
strains of bacteria. The program is currently keeping pace with its ambitious |
11 |
plans and efforts are being focused on fine-tuning the derivatization process |
plans and efforts are being focused on fine-tuning the derivatization process |
12 |
in order to enter the development phase within the next year.</p> |
in order to enter the development phase within the next year.</p> |
13 |
<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202"></p> |
<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202" border=1></p> |
14 |
<p>The goal of PLIVA's second program is to find a novel anti-bacterial compound |
<p>The goal of PLIVA's second program is to find a novel anti-bacterial compound |
15 |
class showing no cross-resistance with current antibiotics. In cooperation with |
class showing no cross-resistance with current antibiotics. In cooperation with |
16 |
Althexis, Boston, USA, a company with leading expertise in structure-based drug |
Althexis, Boston, USA, a company with leading expertise in structure-based drug |